{"id":593905,"date":"2022-03-30T20:46:01","date_gmt":"2022-03-30T20:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=593905"},"modified":"2022-03-30T20:46:01","modified_gmt":"2022-03-30T20:46:01","slug":"metastatic-castrateresistant-prostate-cancer-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-castrateresistant-prostate-cancer-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market_593905.html","title":{"rendered":"Metastatic Castrate-resistant Prostate Cancer Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market"},"content":{"rendered":"
\n
\"Metastatic<\/a><\/div>\n
\n
Metastatic Castration-Resistant Prostate Cancer (mCRPC) <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Metastatic Castration-Resistant Prostate Cancer (mCRPC), historical and forecasted epidemiology as well as the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Metastatic castrate-resistant Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030”.<\/a><\/strong><\/p>\n

DelveInsight’s “Metastatic castrate-resistant Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Metastatic castrate-resistant Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic castrate-resistant Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/strong><\/p>\n

Some of the key facts of the Metastatic castrate-resistant Prostate Cancer Market Report:<\/strong><\/p>\n

    \n
  1. The total prevalent cases of prostate cancer in the 7MM were observed to be 6,742,385 cases in 2017 which is expected to grow during the study period (2017–2030). In total prevalent cases of the 7MM;  the US accounted for the highest number of cases which were 3,170,339 cases in 2017.  <\/li>\n
  2. The total cases of mCRPC in the 7MM were found to be 77,318 in 2017 which is expected to grow during the study period<\/li>\n
  3. In 2017, there were 33,897 cases of mCRPC in the United States, while in Germany these cases were 11,369 which accounted for second-highest cases in the total cases of mCRPC in the 7MM.<\/li>\n
  4. Japan accounted for 10,421 cases of mCRPC in 2017, which is approximately 13% of the total 7MM cases of mCRPC.<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. Metastatic Castrate-resistant Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Metastatic castrate-resistant Prostate Cancer Epidemiology and Metastatic castrate-resistant Prostate Cancer  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Metastatic castrate-resistant Prostate Cancer market report provides insights on the current and emerging therapies.<\/li>\n
    3. Metastatic Castrate-resistant Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Metastatic castrate-resistant Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic castrate-resistant Prostate Cancer market.<\/li>\n<\/ol>\n

      Metastatic Castrate-resistant Prostate Cancer Overview<\/strong><\/p>\n

      Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones and is known as distant or metastatic prostate cancer.<\/p>\n

      Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With mCRPC, cancer no longer completely responds to treatments that lower testosterone and it is found in other parts of the body. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low levels of testosterone.<\/p>\n

      Metastatic CRPC is associated with a poor prognosis and reduced survival. The estimated 5-year survival rate for men with metastatic prostate cancer is around 30% compared to 100% survival in men with localized prostate cancer<\/p>\n

      Metastatic Castrate-resistant Prostate Cancer Market <\/strong><\/p>\n

      The dynamics of the Metastatic castrate-resistant Prostate Cancer market<\/a> is anticipated to change in the coming years owing to the expected launch of emerging therapies such as AstraZeneca, Bristol-Myers Squibb, Janssen Research & Development, Hinova Pharmaceuticals, Hoffmann-La Roche, Pfizer, Astellas Pharma, Clovis Oncology, and others during the forecasted period 2018-2030.<\/strong><\/p>\n

      Learn more by requesting for sample @ Metastatic castrate-resistant Prostate Cancer Market Landscape <\/a><\/strong><\/p>\n

      Metastatic Castrate-resistant Prostate Cancer Pipeline Therapies and Key Companies <\/strong><\/p>\n

        \n
      1. Niraparib: Janssen Research & Development<\/li>\n
      2. Talzenna: Pfizer\/Astellas Pharma<\/li>\n
      3. Opdivo (nivolumab): Bristol-Myers Squibb<\/li>\n
      4. LAE001: Laekna Therapeutics<\/li>\n
      5. Ipatasertib (RG7440): Hoffmann-La Roche <\/li>\n
      6. EPI-7386: ESSA Pharmaceuticals<\/li>\n<\/ol>\n

        Metastatic Castrate-resistant Prostate Cancer Market Drivers <\/strong><\/p>\n